Sanofi Holds Its Ground On Genzyme Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.
You may also be interested in...
Genzyme Jumps First Consent Decree Hurdle
Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.
Genzyme Jumps First Consent Decree Hurdle
Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.
Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.